Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XAGastric in Metastatic Esophagogastric Adenocarcinomas
NCT00447330Phase 2Completed
- Sponsor
- Duke University
- Start
- Feb 2007
- Primary completion
- Jan 2014
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin and bevacizumab in Esophago-Gastric Adenocarcinoma, sponsored by Duke University. Primary endpoint: Progression-Free Survival at 5 years. Started Feb 2007; status: completed.
02
Drugs
capecitabineoxaliplatinbevacizumab
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT00447330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00447330.